[99mTc]Technetium labelled PnAo-azomycin glucuronides: A novel class of imaging markers of tissue hypoxia

Applied Radiation and Isotopes

Volumn 57, Issue 5, 2002, Pages 719-728

  Kumar, Piyush ^a   Wiebe, Leonard I ^a,c   Mannan, Rezaul H ^a   Zhang, Zaihui ^a   Xia, Haiyan ^a   McEwan, Alexander J B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c 3118 Dentistry/Pharmacy Center ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; SYNTHESIS (CHEMICAL); TECHNETIUM; TISSUE; TOXICITY; TUMORS;

LIGANDS;

RADIOISOTOPES;

1 ALPHA BROMO 2,3,4 TRI O ACETYL 6 METHYL GLUCORONATE; 1 BETA DEXTRO (2 NITROIMIDAZOLYL)GLUCURONIC ACID; 2 NITROIMIDAZOLE; GLUCURONIDE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXIME; TECHNETIUM COMPLEX; TECHNETIUM TC 99M PROPYLENE AMINE OXIME;

ARTICLE; BIODIVERSITY; CANCER CELL CULTURE; CYTOTOXICITY; DRUG LABELING; DRUG SELECTIVITY; DRUG SYNTHESIS; FIBROBLAST; HELA CELL; HYPOXIA; IMAGING; IN VIVO STUDY; PRIORITY JOURNAL; SCINTIGRAPHY; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CELL CULTURE; EXPERIMENTAL NEOPLASM; HUMAN; MOUSE; SCINTISCANNING; SYNTHESIS;

ANIMALS; ANOXIA; GLUCURONIDES; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RADIOPHARMACEUTICALS; TUMOR CELLS, CULTURED;

EID: 0036826926     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(02)00188-4     Document Type: Article

References (34)

1. Adams G.E., Flockhart I.R., Smithen C.E., Stratford I.J., Wardman P., Watts M.E. Electron affinic sensitization VIII A correlation between structure, one electron reduction potential and efficiency of nitroimidazoles as hypoxic cell radiosensitizers. Radiat. Res. 67:1976;9-20.
2. 123I]-IAZA as a marker of localized tissue hypoxia in patients with diabetes mellitus. Eur. J. Nucl. Med. 21:1994;1338-1442.
3. Archer, C., personal communication.
4. Archer C.M., Edwards B., Kelly J.D.K., King A.C., Riley A.L.M. Technetium labelled agents for imaging tissue hypoxia in-vivo. Nicolini M., Bandoli G., Mazzi U. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol. 4:1995;535-539 S.G.E. Ditorialli, Padova, Italy.
5. Biaglow J.E., Varnes M.E., Roizen-Towle L., Clark E.P., Epp E.R., Astor M.B., Hall E.J. Biochemistry of reduction of nitroimidazoles. Biochem. Pharmacol. 35:1986;77-90.
6. Brown J.M., Workman P. Partition coefficients as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat. Res. 82:1980;171-190.
7. Castro B.J.R.Dormoy, Evin G., Selve C. Reactifs de couplage peptidique IV (1)-l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.). Tet. Lett. 14:1975;1219-1222.
8. Chapman J.D., Franko A.J., Sharplin J. A marker for hypoxic cells in tumours with clinical applicability. Br. J. Cancer. 43:1981;546-550.
9. Chapman J.D., Baer K., Lee J. Characteristics of the metabolism induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 43:1983;1523-1528.
10. Chernyak A.Y., Sharma G.V.M., Kononov L.O., Radhakrishna P., Kochetkov N.K. Synthesis of glucuronamides of amino acids, constituents of microbial polysaccharides and their conversion into neoglycoconjugates of copolymer type. Glycoconjugate J. 8:1991;82-89.
11. 14C-misonidazole to hypoxic cells in V79 spheroids. Br. J. Cancer. 51:1985;229-235.
12. Groshar D., McEwan A.J.B., Parliament M.B., Urtasun R.C., Golberg L.E., Hoskinson M., Mercer J.R., Mannan R.H., Wiebe L.I., Chapman J.D. Imaging tumor hypoxia and tumor Perfusion. J. Nucl. Med. 34:1993;885-888.
13. 99mTc-HL91, in normoxic, hypoxic, ischemic and stunned myocardium. J. Med. Chem. 41(6):2000;1102-1107.
14. Jette D.C., Wiebe L.I., Flanagan R.J., Lee J., Chapman J.D. Iodoazomycin riboside [1-(5′-Iodo-5′-deoxy-ribofuranosyl-2-nitroimidazole], a Hypoxic Cell Marker. I. Synthesis and in vivo Characterization. Radiat. Res. 105:1986;169-179.
15. 99mTc-nitroheterocycle in a swine model of occlusion and reperfusion. J. Nucl. Med. 41(7):2000;1237-1243.
16. Linder K.E., Chan Y.W., Cyr J.E., Novotnik D.P., Eckelman W.C., Nunn A.D. Synthesis, characterization and in-vitro evaluation of nitroimidazole-BATO complexes. New technetium compounds designed for imaging hypoxic tissues. Bioconjugate Chem. 4:1993;326-333.
17. 99mTc(PnAO-1-2-nitroimidazole) [BMS-181321], a new technetium containing nitroimidazole complex for imaging hypoxia. synthesis, characterization and xanthine oxidase catalyzed reduction J. Med. Chem. 37:1994;9-17.
18. Linder, K.E., Chan, Y-W., Cyr, J.E., Nunn, A.D., 1995. The chemistry of the novel propylene amine oxa Tc-nitroimidazole complex, BMS-194796. Eleventh International Symposium on Radiopharmaceutical Chemistry. Vancouver, Canada, pp. 202-204.
19. Mannan, R.H., 1991. Novel Non-Invasive Markers of Tumor Hypoxia. Ph.D. thesis, University of Alberta, Edmonton, Canada, pp. 89-90 and 145-146.
20. Mannan R.H., Somayaji V.V., Lee J., Mercer J.R., Chapman J.D., Wiebe L.I. Radioiodinated 1-(5-iodo-5′-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodo azomycin arabinoside; IAZA). a novel marker of tissue hypoxia J. Nucl. Med. 32:1991;1764-1770.
21. McEwan A.J.B., Skeith K.J., Mannan R.H., Davies N., Jamali F., Schmidt R., Golberg K., Wiebe L.I. Iodine-123 iodoazomycin arabinoside (IAZA) may have a role in imaging rheumatoid arthritis. J. Nucl. Med. 38(Suppl.):1997;300-301.
22. Parliament M.B., Chapman J.D., Urtasun R.C., McEwan A.J., Golberg L., Mercer J.R., Mannan R.H., Wiebe L.I. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside. preliminary report of a clinical study Br. J. Radiol. 65:1991;90-95.
23. Rasey J.S., Grunbaum Z., Magee S., Nelson N.J., Olive P.L., Durand R.E., Krohn K.A. Characterization of radiolabelled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 111:1987;292-304.
24. Rumsey W.L., Patel B., Kuczynski B., Narra R.K., Chan Y.W., Linder K.E., Cyr J., Raju N., Ramalingam K., Nunn A.D. Potential of nitroimidazoles as markers of hypoxia in heart. Vaupel P.et al. Oxygen Transport to Tissue. 1994;263-270 Plenum, New York.
25. Rumsey W.L., Patel B., Linder K.E. The effect of graded hypoxia on the retention of a novel 99mTc nitroheterocycle in the perfused rat heart. J. Nucl. Med. 36(4):1995;632-636.
26. Silverstein, R.M., Bassler, G.C., Morrill, T.C., 1981. Proton magnetic Resonance Spectroscopy. Spectrometric Identification of Organic Compounds, 4th Edition. John Wiley & Sons, New York, pp. 181-303.
27. Tomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 9:1955;539-549.
28. Urtasun R.C., Coleman C.N., Wasserman T.D., Phillips T.L. Clinical trials with hypoxic cell sensitizers. time to retrench or time to push forward Int. J. Radiat. Oncol. Biol. Phys. 10:1984;1691-1696.
29. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1263-1267.
30. 2 at the cellular level. Br. J. Cancer. 54:1986;453-457.
31. Urtasun R.C., Parliament M.B., McEwan A.J., Mercer J.R., Mannan R.H., Wiebe L.I., Morin C., Chapman J.D. Measurement of hypoxia in human tumours by non-invasive spect imaging of azomycin arabinoside. Br. J. Cancer. 74:1996;S209-S212.
32. Vinjamuri S., O'Driscol K., Maltby P., McEwan A.J., Wiebe L.I., Critchley M. Identification of Hypoxic Regions in Traumatic Brain Injury. Clin. Nucl. Med. 24:1999;891-892.
33. Zhang Z., Mannan R.H., Wiebe L.I., McEwan A.J. Development of a new technetium complex for hypoxia imaging. a technetium(v) amine nitrophenol complex Nicolini M., Bandoli G., Mazzi U. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol. 4:1995;307-312 S.G.E. Ditorialli, Padova, Italy.
34. 99mTc-1-[(diphenylphosphino/mercapto)acetylglycylglycyl-2- aminoethyl]-2-nitroimidazoles as markers of tissue hypoxia. Nicolini M., Mazzi U. Technetium and Rhenium in Chemistry and Nuclear Medicine. Vol. 5:1999;581-588 S.G.E. Ditorialli, Padova, Italy.